肺癌中PVT1的表达及调控机制  

Expression and regulation mechanism of PVT1 in lung cancer

作　　者：蒋嘉 李卫东 丁先锋[1] JIANG Jia;LI Weidong;DING Xianfeng(School of Life Science and Medicine,Zhejiang Sci-Tech University,Hangzhou 310018,China)

机构地区：[1]浙江理工大学生命科学与医药学院,杭州310018

出　　处：《浙江理工大学学报（自然科学版）》2020年第2期246-252,共7页Journal of Zhejiang Sci-Tech University(Natural Sciences)

基　　金：浙江省自然科学基金项目(LY18C050006);国家自然科学基金项目(81602648)。

摘　　要：长非编码RNA(Long non-coding RNA,lncRNA)是非编码RNA家族中的一员,近期的研究发现lncRNA在许多癌症的发生发展中起重要作用。从TCGA数据库中筛选出在肺癌样本中具有较大差异表达的5条lncRNA,利用RT-qPCR检测临床肺癌、癌旁组织以及肺部陈旧性病灶患者血浆中这些lncRNA表达变化,并对其中差异表达最显著的一条lncRNA进行生物信息学分析。RT-qPCR结果显示:LINC00467在肺癌和癌旁组织中无显著差异,CDKN2A-AS1与MIR31HG在肺癌组织中呈现表达下调,而EXOC3-AS1和PVT1在肺癌组织中表达上调,其中PVT1在肺癌中表达上调最为明显。预测结果显示有5条肺癌相关的miRNA可以与PVT1相互作用,并且存在92条miRNA的潜在靶标,揭示肺癌中PVT1竞争性内源RNA的调节机制,为更进一步了解肺癌的发生和发展奠定了基础。Long non-coding RNA(LncRNA)is a member of the non-coding RNA family.Recent studies have found that lncRNA plays an important role in theoccurrence and development of many tumors.In this study,5 lncRNAs with large expression differences in lung cancer samples were screened out from the TCGA database,and lncRNA expression changes in clinical lung cancer,para-carcinoma tissues and the plasma of old lung lesions were detected by RT-qPCR.Besides,one lncRNA with the most significant expression was analyzed by bioinformatics.The results of RT-qPCR showed that the LINC00467 had no significant difference in lung carcinoma tissue and para-carcinoma tissue.The expression of CDKN2A-AS1 and MIR31HG in lung cancer tissues was reduced,while the expression of EXOC3-AS1 and PVT1 increased in lung cancer tissues,and PVT1 was most significantly up-regulated in lung cancer.The predicted results showed that 5 miRNAs related to lung cancer could interact with PVT1,and the potential target genes of 92 mRNAs were predicted,revealing the regulation mechanism of PVT1 competitive endogenous RNA in lung cancer.This paper lays the foundation for further understanding the occurrence and development of lung cancer.

关 键 词：肺癌 lncRNA PVT1 调控机制 

分 类 号：R730-2[医药卫生—肿瘤]